

15 Abstracts from EUSTAR Clinical Projects were presented at EULAR 2025:

### Oral Presentations:

- [Anti-Ro/SSA+/RF+ double seropositivity in systemic sclerosis is associated with more severe interstitial lung disease: A study from the EUSTAR database](#) – Blaž Burja (*Zurich, Switzerland*)
- [Evidence-based detection of progression of systemic sclerosis-interstitial lung disease patients: the EUSTAR-PPF study \(CP number 148\)](#) – Corrado Campochiaro (*Milan, Italy*)
- [Can vasoactive vasodilating drugs influence progression and prognosis of systemic sclerosis-associated interstitial lung disease A EUSTAR cohort study](#) – Adela-Cristina Sarbu (*Bern, Switzerland*)
- [Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease \(SSc-ILD\): results from an EUSTAR cohort study](#) – Devis Benfaremo (*Ancona, Italy*)
- [Clinically significant events are better early indicators of disease progression in Systemic Sclerosis beyond ACR/EULAR criteria: insights from the VEDOSS EUSTAR cohort](#) – Stefano Di Donato (*Leeds, United Kingdom*)
- [Disease characteristics of anti-centromere positive systemic sclerosis patients and risk factors for organ involvement: data from the EUSTAR cohort](#) – Jelena Colic (*Belgrade, Serbia*)  
(An EMEUNET Top 10 Abstract Winner!)
- [The clinical phenotype of anti-Th/To+ patients in Systemic Sclerosis: a case-control study within the European Scleroderma Trials and Research \(EUSTAR\) cohort](#) – Liala Moschetti (*Brescia, Italy*)
- [Clinical Characteristics and Risk Factors for Calcinosis Cutis in Systemic Sclerosis: Insights from the European Scleroderma Trial and Research Group \(EUSTAR\) database](#) – Aslihan Avanoğlu Guler (*Ankara, Türkiye*)
- [Risk factors for cancer in systemic sclerosis, impact on disease phenotype and prognosis, and proposal of machine learning-based personalized screening strategies: insights from an EUSTAR study](#) – Antonio Tonutti (*Pieve Emanuele, Italy*)
- [Association between vasoactive-vasodilating therapy and reduced detection of pre-capillary pulmonary hypertension in systemic sclerosis: evidence from a EUSTAR study](#) – Nicola Farina (*Milan, Italy*)
- [Initial Therapy in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Improves Outcomes Across Haemodynamic Thresholds and Risk Stratification: Insights From the EUSTAR Database](#) – Hilde Jenssen Bjørkekjær (*Kristiansand, Norway*)
- [Vasodilation reduces the risk of new onset of interstitial lung disease in systemic sclerosis: an association study from the EUSTAR database](#) – Cosimo Bruni (*Zurich, Switzerland*)

### Poster Presentations:

- [Interstitial Lung Disease in Anti-U1RNP Systemic Sclerosis Patients: Updated results from the European Scleroderma Trials and Research \(EUSTAR\) Database](#) – Gonçalo Boleto (*Lisbon, Portugal*)
- [Increased frequency of anti-RNA Polymerase 3 antibodies in patients with Systemic Sclerosis and Silicone Breast Implants: a multicentre study from the international EUSTAR cohort](#) – Maria Grazia Lazzaroni (*Brescia, Italy*)
- [Applicability of the phase 3 Trial DAISY \(Detecting effectiveness of Anifrolumab In SYstemic Sclerosis\) inclusion criteria to the general SSc population – a study from the EUSTAR cohort](#) – Emily Kaye (*Leeds, United Kingdom*)